Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Kestra Medical Technologies in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Kestra Medical Technologies’s 10-K, filed July 14, 2026.
- Filed
- Jul 14, 2026, 5:16 PM EDT
- Fiscal year
- FY2026
- Accession
- 0001193125-26-303397
| Line item | Year Ended April 30, 2026 | Year Ended April 30, 2025 |
|---|---|---|
| Cost of revenue | 46,263 | 35,605 |
| Gross profit | 48,863 | 24,210 |
| Operating expenses: | ||
| Research and development | 19,484 | 15,652 |
| Selling, general and administrative | 164,120 | 114,936 |
| Total operating expenses | 183,604 | 130,588 |
| Loss from operations | (134,741) | (106,378) |
| Other expense (income): |
Item 16. Form 10-K Summary.
FAQ
- What is Kestra Medical Technologies's R&D?
- Kestra Medical Technologies (KMTS) reported R&D of $5.63M in Q1 2026.
- How has Kestra Medical Technologies's R&D changed year-over-year?
- Kestra Medical Technologies's R&D increased by 4.6% year-over-year, from $5.39M to $5.63M.
- What is the long-term trend for Kestra Medical Technologies's R&D?
- Over 2 years (2024 to 2026), Kestra Medical Technologies's R&D has grown at a 12.2% compound annual growth rate (CAGR), from $15.49M to $19.49M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Kestra Medical Technologies's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude